These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8427721)

  • 1. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.
    Del Favero A; Menichetti F
    Eur J Cancer; 1993; 29A Suppl 1():S2-6. PubMed ID: 8427721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.
    Maschmeyer G
    Drugs; 1993; 45 Suppl 3():73-80. PubMed ID: 7689455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients.
    Cruciani M; Malena M; Bosco O; Nardi S; Serpelloni G; Mengoli C
    J Clin Oncol; 2003 Nov; 21(22):4127-37. PubMed ID: 14615441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
    Martino R; Subira M; Altés A; López R; Sureda A; Domingo-Albós A; Pericas R; Brunet S
    Acta Haematol; 1998; 99(4):206-11. PubMed ID: 9644298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
    Ann Intern Med; 1991 Jul; 115(1):7-12. PubMed ID: 2048868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients.
    Mori S; Ohashi K; Akiyama H; Shoji H; Sato H; Tanikawa S; Sakamaki H; Onozawa Y
    Kansenshogaku Zasshi; 1994 Jul; 68(7):872-8. PubMed ID: 8089554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of quinolones in the prevention of gram-negative bacteremia in neutropenic cancer patients and in the treatment of enteric infections.
    Bow EJ; Louie TJ
    Clin Invest Med; 1989 Feb; 12(1):61-8. PubMed ID: 2646056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of fluoroquinolones as prophylactic agents in patients with neutropenia.
    Patrick CC
    Pediatr Infect Dis J; 1997 Jan; 16(1):135-9; discussion 160-2. PubMed ID: 9002124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients.
    Van der Auwera P; Gérain J
    Drugs; 1993; 45 Suppl 3():81-90. PubMed ID: 7689457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fluoroquinolones as treatment for infections caused by gram-positive bacteria.
    Cruciani M; Bassetti D
    J Antimicrob Chemother; 1994 Mar; 33(3):403-17. PubMed ID: 8040107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
    Bow EJ
    Curr Opin Infect Dis; 2011 Dec; 24(6):545-53. PubMed ID: 22001945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials.
    Krcméry V
    Drugs; 1995; 49 Suppl 2():139-43. PubMed ID: 8549284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients.
    Freifeld A; Pizzo P
    Pediatr Infect Dis J; 1997 Jan; 16(1):140-5; discussion 145-6, 160-2. PubMed ID: 9002125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of the febrile neutropenic patient.
    Picazo JJ;
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S120-2; discussion S133-40. PubMed ID: 16243492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protecting neutropenic patients from bowel-derived organisms.
    Warren RE
    J Hosp Infect; 1991 Sep; 19 Suppl C():43-58. PubMed ID: 1684195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of fever in neutropenic patients.
    Bodey GP; Rolston KV
    J Infect Chemother; 2001 Mar; 7(1):1-9. PubMed ID: 11406750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones.
    Bow EJ; Loewen R; Vaughan D
    Clin Infect Dis; 1995 Apr; 20(4):907-12. PubMed ID: 7795093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prophylaxis with fluoroquinolones in patients with neutropenia].
    Brodsky AL; Minissale CJ; Melero MJ; Sánchez Avalos JC
    Medicina (B Aires); 1993; 53(5):401-7. PubMed ID: 8201928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations, but must be used wisely.
    Bow EJ
    J Natl Compr Canc Netw; 2004 Sep; 2(5):433-44. PubMed ID: 19780252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.